CN108743602A - 羟基红花黄色素b在制备治疗乳腺癌药物中的应用 - Google Patents
羟基红花黄色素b在制备治疗乳腺癌药物中的应用 Download PDFInfo
- Publication number
- CN108743602A CN108743602A CN201810980739.1A CN201810980739A CN108743602A CN 108743602 A CN108743602 A CN 108743602A CN 201810980739 A CN201810980739 A CN 201810980739A CN 108743602 A CN108743602 A CN 108743602A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- cell
- carthamin
- sydroxy carthamin
- sydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 41
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 41
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 title claims abstract description 35
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000006907 apoptotic process Effects 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 6
- 230000025084 cell cycle arrest Effects 0.000 claims abstract description 5
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims description 3
- 238000011160 research Methods 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000208809 Carthamus Species 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930002878 anthoxanthin Natural products 0.000 description 1
- 150000004637 anthoxanthins Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810980739.1A CN108743602B (zh) | 2018-08-27 | 2018-08-27 | 羟基红花黄色素b在制备治疗乳腺癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810980739.1A CN108743602B (zh) | 2018-08-27 | 2018-08-27 | 羟基红花黄色素b在制备治疗乳腺癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108743602A true CN108743602A (zh) | 2018-11-06 |
CN108743602B CN108743602B (zh) | 2021-02-26 |
Family
ID=63966535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810980739.1A Active CN108743602B (zh) | 2018-08-27 | 2018-08-27 | 羟基红花黄色素b在制备治疗乳腺癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108743602B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1876161A (zh) * | 2005-05-12 | 2006-12-13 | 贵阳云岩西创药物科技开发有限公司 | 治疗乳腺增生的乳癖康药物制剂及制法和质量控制方法 |
WO2011026401A1 (zh) * | 2009-09-01 | 2011-03-10 | 奇复康药物研发(苏州)有限公司 | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 |
CN106083788A (zh) * | 2016-06-24 | 2016-11-09 | 南京中医药大学 | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 |
US9844577B1 (en) * | 2017-04-18 | 2017-12-19 | Fang-Ping Chao | Medicinal composition for prevention or treatment retinal ischemia |
CN108392486A (zh) * | 2018-01-23 | 2018-08-14 | 滨州医学院 | 羟基红花黄色素b在防治心肌缺血再灌注损伤方面的应用 |
-
2018
- 2018-08-27 CN CN201810980739.1A patent/CN108743602B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1876161A (zh) * | 2005-05-12 | 2006-12-13 | 贵阳云岩西创药物科技开发有限公司 | 治疗乳腺增生的乳癖康药物制剂及制法和质量控制方法 |
WO2011026401A1 (zh) * | 2009-09-01 | 2011-03-10 | 奇复康药物研发(苏州)有限公司 | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 |
CN102000072A (zh) * | 2009-09-01 | 2011-04-06 | 奇复康药物研发(苏州)有限公司 | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 |
CN106083788A (zh) * | 2016-06-24 | 2016-11-09 | 南京中医药大学 | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 |
US9844577B1 (en) * | 2017-04-18 | 2017-12-19 | Fang-Ping Chao | Medicinal composition for prevention or treatment retinal ischemia |
CN108392486A (zh) * | 2018-01-23 | 2018-08-14 | 滨州医学院 | 羟基红花黄色素b在防治心肌缺血再灌注损伤方面的应用 |
Non-Patent Citations (5)
Title |
---|
CHUANJUN QU ET AL: "Inhibitory Effect of Hydroxysafflor Yellow B on the Proliferation of Human Breast Cancer MCF-7 Cells", 《RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY》 * |
SHIJUN YUE ET AL: "Two New Quinochalcone C-Glycosides from the Florets of Carthamus tinctorius", 《INT. J. MOL. SCI》 * |
YUYING LI ET AL.: "Hydroxysafflor yellow A induces apoptosis in MCF-7 cells by blocking NFkB/p65 pathway and disrupting mitochondrial transmembrane potential", 《RSC ADVANCES》 * |
陈梦: "羟基红花黄色素A的植物雌激素样作用及机制研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
黄玲玲等: "红花有效成分抗肿瘤机制研究进展", 《江西中医药》 * |
Also Published As
Publication number | Publication date |
---|---|
CN108743602B (zh) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oyeleke et al. | Antibacterial activity of Ficus capensis | |
CN104840482B (zh) | 一种中药有效组分组合物及其用途 | |
CN108853358B (zh) | 一种抗菌中药组合物及其制备方法和用途 | |
CN110433188A (zh) | 蓝花参提取物在制备治疗或预防炎症性肠病的药物中的应用 | |
CN102688280A (zh) | 一种抗辐射中药发酵液的制备 | |
CN108743602A (zh) | 羟基红花黄色素b在制备治疗乳腺癌药物中的应用 | |
CN105613285B (zh) | 一种快速提高丹参中迷迭香酸含量的方法 | |
CN101695511B (zh) | 石榴皮提取物及其生产方法和应用 | |
CN112402413B (zh) | 野马追倍半萜内酯b在制备抗肝癌药物中的应用及一种抗肝癌药物 | |
CN107708727A (zh) | 一种用于治疗肝癌的肿瘤疫苗及其制备方法 | |
CN109331051A (zh) | 沙枣树叶提取物及其提取方法和应用 | |
CN107708728A (zh) | 一种用于治疗胃癌的肿瘤疫苗及其制备方法 | |
CN105481799A (zh) | 一种高度氧化的倍半萜类化合物及其制备方法和医药用途 | |
CN106177035B (zh) | 具有降血糖、抗癌的月季花有效提取物的制备方法及应用 | |
CN109985229A (zh) | 化合物ilamycin C及其同系物在制备治疗三阴乳腺癌药物中的应用 | |
CN104398520B (zh) | Ruxolitinib在制备治疗M2型急性髓系白血病药物中的应用 | |
CN101653462B (zh) | 植物病毒在制备治疗恶性肿瘤的药物中的应用 | |
CN107095890B (zh) | 桐花树叶石油醚提取物及其制备和治疗结肠癌的应用 | |
CN113797191B (zh) | 一种化合物治疗血管增生相关疾病以及抗肿瘤的用途 | |
CN106822163A (zh) | 一种协同促进细胞凋亡治疗人乳腺癌组合物 | |
CN107095889A (zh) | 桐花树叶石油醚提取物及其制备和治疗前列腺癌的应用 | |
CN107519480A (zh) | Trail与穿心莲内酯联用在对抗肾癌细胞耐药性中的应用 | |
Gupta et al. | Herbal Plant Extracts of Gentianakurroo and Rauwolfia serpentine Its Implications In-Breast Cancer | |
KR20230126887A (ko) | 항암 활성을 가지는 폴리포루스 튜버래스터 균주 배양방법 | |
CN117815211A (zh) | 一种益智单体蓝桉醇在制备抗肝癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of hydroxysafflower yellow B in preparation of drugs for breast cancer Effective date of registration: 20211214 Granted publication date: 20210226 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: BINZHOU MEDICAL University Registration number: Y2021980014859 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210226 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: BINZHOU MEDICAL University Registration number: Y2021980014859 |